Led · Series C · Jan 2022

Circuit Clinical operates an integrated research organization (IRO) and patient engagement business that connects physicians, sites, and patients to clinical research. The company has a network representing over 90 doctors across more than 30 site locations, a nationally accredited cancer center, and a database of more than 2.5 million potential trial participants. Its offering includes an award-winning patient engagement platform, TrialJourney, and spans 10 therapeutic areas including oncology, cardiovascular disease, diabetes, women’s health, and others. Circuit Clinical positions clinical research as a care option and focuses on improving retention, decreasing patient burden, and enhancing the patient experience. As part of a new strategic partnership, all Circuit Clinical sites will be standardized on Medidata’s RAVE and myMedidata technology solutions to enable turnkey decentralized and hybrid trial programs. The company plans to expand its decentralized clinical trial (DCT) network to 500 physician investigators and reach 15 million patients through the partnership. Medidata’s strategic investment in Circuit Clinical’s $27M Series C will fund that expansion and technology integration. Circuit Clinical is an integrated research organization (IRO) headquartered in Buffalo, NY that began conducting clinical research within physicians' practices in 2015. It partners with a multi-specialty network of physician practices and multiple Accountable Care Organizations to offer patients access to clinical trials in their own doctors' offices. Its core product, TrialScout™, is a ratings-and-reviews platform and patient-facing trial finder designed to help patients find, choose, and rate clinical trial experiences. The company combines technology-enabled services with in-office research teams to rapidly find and enroll the right patients and support retention through study completion. As a 43North 2019 competition winner, Circuit Clinical received a $500,000 cash investment and one year of free incubator space, plus mentorship, investor-network access, and marketing and hiring support. The company is positioning to transform the patient experience of finding and participating in clinical trials through its platform and service model.

Participated · Series B · Aug 2021

AllStripes has developed a technology platform that generates regulatory‑ready evidence and a patient application that enables patients and families to securely participate in rare disease research online. The company partners with biopharmaceutical firms, academic centers, and patient advocacy organizations to run real‑world evidence studies and support therapeutic discovery. AllStripes is a public benefit corporation and emphasizes transparent data collection and sharing across the life sciences continuum. It reports partnerships with more than 30 patient advocacy organizations across 40 conditions and is supporting more than 3,000 users to date. The platform is being expanded with enhancements to data automation, user experience, and life‑sciences offerings to improve research insights. The company plans to grow its global operational footprint and team while launching 100 new rare disease research programs. RDMD has developed an FDA-ready technology platform and a patient application that generate regulatory-grade real-world clinical evidence to accelerate research and drug development for rare diseases. The platform centralizes patient medical records and gives patients and families secure access and ownership of their data while enabling remote participation in studies. Since founding in 2018, RDMD's patient application has grown to more than 1,000 users across 12 conditions and the company has acquired patient medical information from over 1,500 hospitals. RDMD has expanded internationally to Canada and plans further expansion into Europe. The company plans to expand into 20 additional rare diseases and to be active in more than 30 conditions within a year. RDMD also reports commercial and collaborative partnerships with patient organizations, academic consortiums and biopharmaceutical customers to build regulatory-grade evidence in targeted conditions. RDMD provides an app that compiles fragmented medical records, digitizes handwritten notes and faxes via OCR, and structures the data into disease-specific timelines for patients. Patients can use the app to track treatment, get second opinions, and — if they opt in — allow their de-identified records to be used for research. RDMD sells anonymized, regulation-ready datasets to research organizations, hospitals and pharmaceutical companies to accelerate rare disease R&D. The company emphasizes producing research-grade, regulatory-grade data that can reduce time and cost in rare disease studies. RDMD has enrolled 150 patients with neurofibromatosis to date and plans to expand into additional rare diseases. The startup says collected funds will be used to build out its product and address more rare conditions. The company acknowledges privacy, security and patient trust as central operational considerations.

Participated · Series D · Nov 2017

Syapse combines clinical expertise with smart technologies to transform data into evidence and experience in collaboration with a network of partners. The company is led by CEO Ken Tarkoff and is based in San Francisco and New York. Its core offering includes a Learning Health Network that partners with community health systems to support precision medicine strategies aimed at improving clinical outcomes, reducing costs, and enhancing patient experience. Syapse has also added life sciences partnerships with established biopharmaceutical companies. The company raised $35M in Growth funding and intends to use the funds to expand its focus on providing real-world insights to partners and assist them in improving outcomes for people with cancer. Syapse provides real-world evidence (RWE) and actionable treatment insights through its Syapse Learning Health Network to improve outcomes for people with cancer. The platform standardizes and normalizes de-identified clinical and molecular data across participating healthcare providers to support clinical decisions and research. Syapse has expanded partnerships with community health systems and life sciences companies and has collaborated with the FDA to address urgent public health challenges, including COVID-19. The company positions its network to drive precision medicine strategies that aim to improve clinical outcomes, reduce costs, and enhance patient experience. The announced financing is intended to expand partnering opportunities with life sciences, health systems, regulators, and molecular labs to deliver more real-world insights. Syapse works with leading health systems, life sciences companies, and regulators to accelerate the creation and use of real-world evidence to improve cancer patient outcomes. The company provides insights from real-world data through a portfolio of products that support research and product development, clinical trial patient matching, regulatory filings, and monitoring of commercially approved products. Syapse integrates clinical, molecular, and outcomes data to support large‑scale precision medicine programs at health systems. Its Syapse Learning Health Network is described in the press release as one of the world’s largest networks dedicated to improving outcomes in cancer care through precision medicine. The company recently presented collaborative research with the FDA Office of Clinical Pharmacology and Advocate Aurora Health on pneumonitis incidence at the AACR annual meeting, illustrating its RWE capabilities. Proceeds from the announced financing are intended to accelerate the creation and use of real‑world evidence in oncology and support Syapse’s ongoing collaborations and product development. Syapse develops an oncology software platform and the Syapse Data Sharing Network to enable physicians to view treatments and outcomes for patients across the country and apply that information to improve care. Led by CEO Ken Tarkoff and based in San Francisco, the company sells its platform to large health systems and lists customers including Intermountain Healthcare, Providence St. Joseph Health, Henry Ford Health System, Aurora Health Care, Catholic Health Initiatives and Dignity Health. Syapse recently raised $30m in Series D financing. The company intends to use the funds to expand operations and bring its solutions to more providers and their cancer patients. Its core product focuses on enabling consistent precision-medicine practice across large health systems by connecting treatment and outcome data. The Data Sharing Network is positioned as a clinical-data tool to inform treatment decisions across participating institutions. Syapse provides cloud-based precision medicine software to academic and community health systems to support widespread adoption of precision oncology. The platform integrates clinical, genomic, and other molecular data from medical records, labs, and pharmacies to create a longitudinal patient profile. It offers guidance on diagnostic and therapeutic strategy based on clinical best practices and supports implementation of treatment decisions while coordinating care across geographically dispersed teams. The software also measures patient outcomes to learn what works and improve best practices. Led by CEO Glenn Winokur and based in Palo Alto, Syapse intends to use new funding to expand adoption of its software in community health systems. The company completed the first close of a Series C financing as reported in December 2016.